<DOC>
	<DOCNO>NCT01739400</DOCNO>
	<brief_summary>Long-term study evaluate macitentan safe , tolerable efficient enough use treatment Eisenmenger syndrome .</brief_summary>
	<brief_title>Clinical Study Assess Long-term Safety , Tolerability , Efficacy Macitentan Subjects With Eisenmenger Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Subjects ES ( include Down Syndrome ) complete doubleblind AC055305 / MAESTRO study schedule , i.e. , remain doubleblind study Week 16 ( whether still take study drug end period ) . Subjects prematurely discontinue doubleblind study drug AC055305 / MAESTRO study due : AE assess relate use study drug , elevate liver test ( relate unrelated study drug ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Eisenmenger Syndrome</keyword>
	<keyword>exercise capacity</keyword>
</DOC>